Soy estrogens and breast cancer: Researcher offers overview

May 16, 2007

Are soy products healthy additions to a person's diet, safe alternatives to hormone-replacement therapy or cancer-causing agents" The answer, according to University of Illinois food science and human nutrition professor William Helferich, is, "It depends."

He reviews the science linking breast cancer, soy and dietary supplements that contain soy phytoestrogens this month at a conference on "Diet and Optimum Health" sponsored by the Linus Pauling Institute at Oregon State University.

Helferich has spent a decade evaluating the health effects of isoflavones, a class of plant estrogens present in high concentrations in soy. Much of his work has focused on a single isoflavone, genistein, which occurs in varying concentrations in soy products or ingredients such as tofu, soy protein isolates, soy flour and some estrogenic dietary supplements.

Genistein is of interest because it is the most active of the soy isoflavones, and because it activates estrogen receptors in cells, including some breast tumor cells.

Dozens of studies of the role of human and plant estrogens in breast cancer have yielded seemingly contradictory findings. Some found that feeding genistein to female rats prior to puberty reduced the number of chemically induced mammary tumors. Other studies showed that estradiol, a primary human estrogen, spurs the growth of existing estrogen-dependent breast tumors.

Helferich and colleagues demonstrated that – like estradiol – dietary genistein stimulates the growth of estrogen-responsive tumors. They also found that dietary genistein interferes with treatments, such as tamoxifen, that target estrogen receptors in breast tumors. (About 70 percent of women with breast cancer have estrogen-responsive tumors.)

"The resolution of this paradox may lie in the timing of estrogen administration," Helferich said. Exposure to genistein, an estrogen, before puberty causes mammary gland differentiation. "A differentiated cell undergoes less proliferation and therefore is less likely to progress through the cancer process," he said. "However, if the estrogen is administered to an animal after the development of an estrogen-responsive tumor, the growth of this tumor will be stimulated," he said.

Today Helferich is most concerned about the use of genistein and other isoflavones in supplements sold as "natural" alternatives to hormone-replacement therapy. He notes that midlife women who consume these products perceive them as natural and safe. But women aged 50 and older are also most at risk of developing breast cancer. Helferich is evaluating the biological activity of some of these products, which are available in many forms, do not require a prescription, and in most cases are consumed without the knowledge of their physicians.

Helferich notes that the incidence rate of breast cancer in women aged 50 and over in the U.S. dropped significantly after use of hormone-replacement therapy (HRT) declined in 2002 and 2003. While purified genistein is not as potent as HRT, Helferich said, it still poses a risk to midlife women because the amount consumed is much higher. The labels of many products that contain this and other isoflavones lack vital information about what is actually in their products, he said, and because these are natural products, the consistency from batch to batch is difficult to control.

"Women are participating in an ongoing experiment with an unknown outcome," he said. "You can't identify what dose of isoflavones you're getting."

But genistein is only one component of soy, Helferich said, and studying its effects in purified form may lead to misleading conclusions about the health consequences of soy in the diet. In fact, studies have shown that foods like soy flour have a very different effect.

"The complex mixture found in soy flour doesn't make the tumor grow," Helferich said.

"Whole soy contains a lot of biologically active ingredients, but together they may have multiple effects that can reduce the negative outcomes. When the whole food is consumed you get a very different effect than if you consume the concentrated constituents individually."

All this research points to a very simple truth, Helferich said: The whole soybean is healthier than many of its individual chemical parts.

"That raw food can be consumed for less than a dollar a serving and is likely better for you than that thing you pick up at the health food store for $30 a pound," he said.

Source: University of Illinois at Urbana-Champaign

Explore further: Gene mapping reveals soy's dynamic, differing roles in breast cancer

Related Stories

Gene mapping reveals soy's dynamic, differing roles in breast cancer

April 28, 2015
Scientists have mapped the human genes triggered by the phytonutrients in soy, revealing the complex role the legume plays in both preventing and advancing breast cancer.

Soy isoflavones may accelerate progression of breast cancer

February 25, 2014
Women with estrogen-responsive breast cancer who consume soy protein supplements containing isoflavones to alleviate the side effects of menopause may be accelerating progression of their cancer, changing it from a treatable ...

Recommended for you

Study prompts new ideas on cancers' origins

December 16, 2017
Rapidly dividing, yet aberrant stem cells are a major source of cancer. But a new study suggests that mature cells also play a key role in initiating cancer—a finding that could upend the way scientists think about the ...

What does hair loss have to teach us about cancer metastasis?

December 15, 2017
Understanding how cancer cells are able to metastasize—migrate from the primary tumor to distant sites in the body—and developing therapies to inhibit this process are the focus of many laboratories around the country. ...

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.